TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and often lethal malignancy, requiring the development of enhanced therapeutic approaches. The DNA damage response (DDR) pathway is frequently altered during PDAC development, leading to an increased occurrence of DNA damage. DN...
Saved in:
Main Authors: | Xiao-Mei Tang, Min-Min Shi, Jia-Cheng Wang, Yi-Jin Gu, Yu-Ting Dai, Qin-Xin Yang, Jia Liu, Ling-Jie Ren, Xin-Yun Liu, Chun Yang, Fang-Fang Ma, Ji-Bing Liu, Hong Yu, Da Fu, Yun-Feng Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-02-01
|
Series: | Cell & Bioscience |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13578-025-01350-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparib
by: Xin‐Yuan Lei, et al.
Published: (2024-12-01) -
Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer
by: Jiahao Zhang, et al.
Published: (2025-01-01) -
Asymptotic analysis of mathematical model describing a new treatment of breast cancer using AZD9496 and palbociclib
by: Ophir Nave, et al.
Published: (2025-01-01) -
Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report
by: Linn Z, et al.
Published: (2025-02-01) -
Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell‐free RNA
by: Martin Metzenmacher, et al.
Published: (2025-02-01)